Doucett v. Strominger
Opinion of the Court
Appeal from an order of the Supreme Court (Mulvey, J.), entered December 20, 2012 in Tompkins County, which denied defendant’s motion for summary judgment dismissing the complaint.
Plaintiff was diagnosed with Meniere’s disease,
As the proponent of a motion for summary judgment in a medical malpractice action, defendant “bore the initial burden of establishing that there was no departure from accepted standards of practice or that plaintiff was not injured thereby” (Derusha v Sellig, 92 AD3d 1193, 1193 [2012] [internal quotation marks and citations omitted]; see Helfer v Chapin, 96 AD3d 1270, 1271 [2012]; Maki v Bassett Healthcare, 85 AD3d 1366, 1368 [2011], appeal dismissed 17 NY3d 855 [2011], lv dismissed and denied 18 NY3d 870 [2012]). Here, plaintiff alleged that defendant departed from accepted standards of medical care by, among other things, failing to “reinitiate immunosuppressant therapy” after Endo terminated Methotrexate and plaintiff’s hearing deteriorated. In support of the motion, defendant submitted, among other things, the affidavit of his expert, Benjamin Crane. Crane, an otolaryngologist, noted that defendant was not responsible for commencing or discontinuing the
To that end, plaintiff submitted the affirmation of Fred Holt, an otolaryngologist, who opined that defendant deviated from accepted standards of medical care in the manner in which he treated plaintiff after Endo discontinued Methotrexate therapy. Holt discounted the 2003 study to which defendant and Crane referred as being inconclusive and contradictory to other medical literature that supported Methotrexate therapy for autoimmune hearing loss. He also opined that the results of two hearing tests performed on plaintiff after the discontinuance of Methotrexate, indicating a significant deterioration of plaintiffs hearing, were “red flag[s]” which, considering plaintiffs medical history and the stabilization of his hearing while taking the drug, should have prompted defendant to discuss with plaintiff the option of resuming Methotrexate therapy.
We are unpersuaded by defendant’s contention that Holt’s affirmation was speculative and conclusory and, therefore, insufficient to defeat defendant’s motion (see Carter v Tana, 68 AD3d 1577, 1580 [2009]). The record reflects that Holt referred to prior medical studies, based his opinion on a review of plaintiffs medical record and history and made factual references to plaintiffs treatment. Viewing the evidence in a light most favorable to plaintiff, Holt’s affidavit was sufficient to demonstrate the existence of triable issues of fact both as to whether defendant departed from accepted standards of medical care and whether such departures were a substantial factor in causing plaintiffs injury (see Derusha v Sellig, 92 AD3d at 1195; Hickey v Arnot-Ogden Med. Ctr., 79 AD3d 1400, 1401 [2010]). Accordingly, defendant’s motion for summary judgment was properly denied.
Rose, J.E, McCarthy and Garry, JJ., concur. Ordered that the order is affirmed, with costs.
. According to defendant, Meniere’s disease consists of “fluctuating intermittent vertigo, ear fullness, progressive hearing loss.”
. Plaintiff also named Endo as a defendant. However, Supreme Court dismissed the claims against Endo in an order which is not at issue on this appeal.
. Defendant testified that he was aware of the study to which Endo referred.
. In fact, defendant acknowledged at his deposition that Methotrexate was a viable treatment option in April 2005 and that he should have discussed that option with plaintiff.
Case-law data current through December 31, 2025. Source: CourtListener bulk data.